Chemo Pharma Laboratories Limited (CHEMOPH) Fair Value & Analysis
Healthcare · IN · Market cap ₹196M
Fair value as of: Jul 5, 2026
From 8 valuation models · updated today
Share price −30.2% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹75.00 – ₹145.75 · fair‑value band ₹34.22 – ₹57.03 · the ₹80.25 price screens above the ₹45.63 fair value. As of Jul 5, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Chemo Pharma Laboratories Limited (CHEMOPH) currently trades at ₹80.25, while our model-based Fair Value estimate is ₹45.63 — implying the stock looks roughly 43.1% overvalued today. We read business quality at 55/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Trailing-twelve-month revenue stands at ₹2.3M. Revenue declined 16.7% year over year. Fundamentals as of Jul 5, 2026
Our scenario range runs from ₹34.22 (bear case) to ₹57.03 (bull case); at ₹80.25, the current price sits above that range. The share trades about 48% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -43%, CHEMOPH screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.
About the company
Chemo Pharma Laboratories Limited does not have significant operations. Previously, the company was engaged in the finance and investment activities. Chemo Pharma Laboratories Limited was incorporated in 1942 and is based in Mumbai, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Chemo Pharma Laboratories Limited reported revenue of ₹0 in FY2025 versus ₹0 in FY2021. Reported net income was ₹3.4M in FY2025, compounding +8.2%/yr from FY2021.
Is CHEMOPH fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$102.95 | A$126.79 | +23% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| Moderna, Inc M1RN34 | R$14.75 | R$4.91 | -67% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Chemo Pharma Laboratories Limited (CHEMOPH) undervalued?
What is the fair value of CHEMOPH?
What is the quality score of CHEMOPH?
What is the revenue of Chemo Pharma Laboratories Limited (CHEMOPH)?
What is the net profit margin of CHEMOPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.